Chugai gets rights to Roche melanoma drug vemurafenib in Japan
Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said yesterday that it has entered into a license agreement with Swiss major Roche (ROG: SIX), its majority owner, for the BRAF inhibitor vemurafenib, which has been submitted by Roche for approval in Europe and the USA for mutation-positive metastatic melanoma (The Pharma Letter May 12).
Under the accord, Chugai obtains exclusive rights for the development and marketing of vemurafenib in Japan, and will make milestone payments to Roche. Further financial terms were not disclosed.
Chugai plans to start a Phase I clinical trial in Japan in 2012 for BRAF mutation-positive metastatic melanoma. Further development for other tumor types with BRAF mutations will be considered in accordance with the progress and results of the clinical trials conducted by Roche.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze